Specific renal histopathological findings related to cardiovascular disease risk in patients with CKD

Published Date: 10 Mar 2023

Chronic renal failure (CKD) is a risk factor for cardiovascular diseases such as heart attacks, strokes or heart failure. Brigham the scientist...

Read Full News

Latest News

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Daxdilimab Improves Discoid Lupus in Phase 2, With Victoria Werth, MD Victoria Werth, MD

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

From Injectable to Oral: Optimal Durable Clearance Across the IL-23 Class Linda Stein Gold, MD, Andrew Blauvelt, MD

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Todays Updates

Tailoring Pulmonary Rehab to Close the COPD Gap, With Omid Pourshahid, MD Omid Pourshahid, MD

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Virtual Pulmonary Rehab and Matched Care, With Omid Pourshahid, MD Omid Pourshahid, MD

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

Experts Examine Biologic Coverage in Asthma and COPD

Experts Examine Biologic Coverage in Asthma and COPD

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Type 2 Phenotyping in Asthma and COPD: Clinical Forum Perspectives

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Ralinepag Cuts PAH Worsening in Low-Risk Patients, With Jean Elwing, MD

Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated Marco Meglio

Data from the real-world, CONFIDENCE study found switching from intravenous to subcutaneous ocrelizumab was well tolerated in patients with relapsing and primary progressive MS.

New Phase 2 Trial Evaluates Fenebrutinib Dosing in Children With Relapsing MS Louie Pasculli

The phase 2 FENerations1 study is an open-label, single-arm, small-scale study evaluating fenebrutinib dosing in 8 to 12 children and adolescents with relapsing MS.

Latest News

Nonsurgical Skin Cancer Care and New Approvals, With Todd Schlesinger, MD

Both doses of the anti-ILT7 antibody daxdilimab reduced CLASI-A scores vs placebo at week 24 in moderate-to-severe, treatment-refractory discoid lupus.

5-Year ADlong Data on Lebrikizumab for Eczema, With Stephan Weidinger, MD, PhD

Bitopertin Meets All Endpoints in Phase 3 APOLLO Trial for EPP

Q&A: Nemolizumab Sustains Itch, Skin Gains in Early Responders at 3 Years

Linda Stein Gold, MD, and Andrew Blauvelt, MD, MBA, discuss 2-year ICONIC-TOTAL data supporting icotrokinra's benefit for scalp, genital, and hand/foot PsO.

News All Time

Phase 3 Ritlecitinib Results in Vitiligo, With Iltefat Hamzavi, MD Iltefat Hamzavi, MD

Iltefat H. Hamzavi, MD, discusses phase 3 Tranquillo data showing higher facial and total body repigmentation with ritlecitinib in vitiligo.

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Is Hidradenitis Suppurativa Underdiagnosed in Male Patients?

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Q&A: Comorbidity Screening and Biologic Timing in HS, With Jennifer Hsiao, MD

Nemolizumab Sustains AD Response at 3 Years, With Matthias Augustin, MD Matthias Augustin, MD

Up to 91% of patients reached EASI-75 at week 152 in the ARCADIA LTE, with consistent safety and gains in itch and quality of life.

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Denifanstat Sustains Acne Improvement Through 52 Weeks in Phase 3 Extension

Upadacitinib Feasible for Palmoplantar Pustulosis: David Gleeson, BM BCH David Gleeson, BM BCH

Gleeson discusses JAKPPPOT data showing the therapy met all feasibility thresholds with a markedly larger response than historic placebo in PPP.

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Atopic Dermatitis Pipeline and Remibrutinib Approval for Dermographism

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

Nemolizumab Sustains Atopic Dermatitis Skin, Itch Control Through 3 Years

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

How Dermatologists Can Sort Through Skincare and Cosmeceutical Claims

Navigating Corticosteroid Stewardship in Dermatology, With Kristina Derrick, MD Kristina Derrick, MD

Kristina Derrick, MD, explains how prior authorization and cost limit steroid-sparing care, and how dermatologists can document corticosteroid exposure.

Denifanstat Sustains Acne Control Through 52 Weeks, With Neal Bhatia, MD Neal Bhatia, MD

Bhatia discusses 52-week extension data showing denifanstat sustained acne control with a favorable long-term safety profile, presented at EADV 2026.

Moving Corticosteroid Stewardship into Policy, With Killian Lozach, MBA Killian Lozach, MBA

Lozach outlines how the Corticosteroid Stewardship Alliance plans to bring clinician data and adverse event costs to payers and lawmakers.

Conference Preview: Fall Clinical Dermatology Conference 2026

Conference Preview: Fall Clinical Dermatology Conference 2026

Tips on Optimizing HS Biologics, Combinations, and Surgery

Tips on Optimizing HS Biologics, Combinations, and Surgery

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

Remibrutinib Receives FDA Approval for Symptomatic Dermographism

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

EADV 2026: TNFα, OX40L Cluster at HS Draining Tunnels

Recommended News For You

More Data Back Teclistamab for Autoimmune Disease

C/EBP? works in tandem with MYB to sustain AML cells' oncogenic program.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

Shorter, less intense regimen still effective for HPV-linked throat cancer, study shows

Screening tests that are non-invasive show promise in detecting colorectal cancer.

The FDA approves alexinib as an adjuvant treatment for non-small cell lung cancer.

The standard for high-risk prostate cancer is supported by a study using high-dose RT and long-term ADT.

Recommended Articles For You

Clinical Pharmacology of Drug Exposure During Long-Term Cancer Survivorship 

Theranostics and Radioligand Therapy: Precision Cancer Care with Targeted Radionuclides 

Unlocking the Mysteries of Rhabdomyoma: A New Hope for Treatment 

The Benefits and Risks of Transurethral Resection of Bladder Tumor  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

J. Craig Venter, Who Won the Race to Sequence the Human Genome, Dies at 79

2.

Three out of ten breast cancers detected between screenings, study finds

3.

MRD Tied to PFS in Lymphoma Patients on Epcoritamab

4.

AI can identify women at risk of breast cancer years in advance: Study

5.

Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.

1.

Interpreting Iron Studies: What Your Blood Results Really Mean 

2.

The Mysterious Pain of Scrotal Hematoma: A Guide to Diagnosis and Treatment

3.

Beyond the Blinders: A Review of Targeted Therapeutic Strategies for Triple-Negative Breast Cancer in 2025

4.

Digital Oncology Ecosystems Integrating Longitudinal Patient Trajectories: Transforming Cancer Care through Data-Driven Innovation

5.

Preventing Treatment-Related Secondary Malignancies: Evidence-Based Strategies for Clinical Practice

1.

International Conference on Innovations in Critical Care for Oncology and Cardiology

2.

International Conference on Oncology, Cardiology and Critical Care Policy

3.

International Conference on Oncology, Cancer Prevention and Public Health

4.

International Conference on Cancer Nursing and Rehabilitation Strategies

5.

International Conference on Best Practices in Oncology, Cardiology and Critical Care

1.

Navigating the Complexities of Ph Negative ALL - Part IV

2.

Navigating the Complexities of Ph Negative ALL - Part XVI

3.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

4.

Signs and Symptoms of Leukemia

5.

The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot